血清免疫球蛋白游离轻链(FLC)κ和λ测定是浆细胞病诊断和疗效分析及预后判断的重要工具.FLC分析与血清蛋白电泳和免疫固定电泳联合可明显提高浆细胞病诊断的敏感性,并在除轻链淀粉样变性外的其它疾病中替代24 h尿液检查.基础FLC可预测各种浆细胞病的预后.对轻链淀粉样变性、寡分泌型和非分泌型骨髓瘤,可通过FLC分析进行定量监测.对轻链淀粉样变性,连续FLC检测优于蛋白电泳和免疫固定电泳.%The serum immunoglobulin-free light chain (FLC) assay measures levels of free κ and λ immunoglobulin light chains and is an invaluable tool in the evaluation and management of multiple myeloma and related plasma cell disorders (PCD). The serum FLC assay in combination with serum protein electrophoresis (SPEL) and immunofixation yields high sensitivity of screening, and negates the need for 24 h urine studies for diagnoses other than light chain amyloidosis (AL). The baseline FLC measurement is of major prognostic value in virtually every PCD. The FLC assay allows for quantitative monitoring of patients with oligosecretory PCD,including AL, oligosecretory myeloma and non-secretory myeloma. In AL patients, serial FLC measurements outperform SPEL and immunofixation.
展开▼
